BACKGROUND: Chronic spontaneous urticaria might affect elderly patients, causing a serious impairment of their quality of life. The therapeutic management of the elderly patient is challenging; in fact, the first-line recommended therapy for symptom control are antihistamines, that may have interactions or increased risk of side effects in patients with comorbidities and poly-pharmacological regimen. Omalizumab is the first biological drug approved for chronic spontaneous urticaria resistant to antihistamines. Real-life data focusing on patients >65years old (yoa) treated with omalizumab are rare.METHODS: In our retrospective study, we evaluated the efficacy and safety of this biologic therapy in patients over 65yoa. We performed Urticaria Activity Score-7 (UAS-7) in order to evaluate the efficacy of omalizumab and the time of remission. We collected any adverse event related to the treatment. Moreover, we investigated the presence of comorbidities and their impact on the efficacy of omalizumab.RESULTS: 63 patients, with a mean age of 72.3 ±5.6years, range: 65-89) were enrolled. Of 63 subjects, 23 (36.5%) had an "early complete response" profile, which means the achievement of a UAS7 score of "0" within the first 7days of therapy. The most frequent comorbidity was hypertension, which affected 26/63 (41.3%) patients; no adverse events were reported. No significant correlations were found between treatment effectiveness and comorbidities.CONCLUSIONS: omalizumab is a safe and effective therapy also in elderly patients with multiple comorbidities. This article is protected by copyright. All rights reserved.

It's Never Too Late To Treat Chronic Spontaneous Urticaria With Omalizumab: Real-Life Data From A Multicenter Observational Study Focusing on Elderly Patients / Martina, Emanuela; Damiani, Giovanni; Grieco, Teresa; Foti, Caterina; Pigatto, Paolo Daniele Maria; Offidani, Annamaria. - In: DERMATOLOGIC THERAPY. - ISSN 1396-0296. - (2021), p. e14841. [10.1111/dth.14841]

It's Never Too Late To Treat Chronic Spontaneous Urticaria With Omalizumab: Real-Life Data From A Multicenter Observational Study Focusing on Elderly Patients

Grieco, Teresa;
2021

Abstract

BACKGROUND: Chronic spontaneous urticaria might affect elderly patients, causing a serious impairment of their quality of life. The therapeutic management of the elderly patient is challenging; in fact, the first-line recommended therapy for symptom control are antihistamines, that may have interactions or increased risk of side effects in patients with comorbidities and poly-pharmacological regimen. Omalizumab is the first biological drug approved for chronic spontaneous urticaria resistant to antihistamines. Real-life data focusing on patients >65years old (yoa) treated with omalizumab are rare.METHODS: In our retrospective study, we evaluated the efficacy and safety of this biologic therapy in patients over 65yoa. We performed Urticaria Activity Score-7 (UAS-7) in order to evaluate the efficacy of omalizumab and the time of remission. We collected any adverse event related to the treatment. Moreover, we investigated the presence of comorbidities and their impact on the efficacy of omalizumab.RESULTS: 63 patients, with a mean age of 72.3 ±5.6years, range: 65-89) were enrolled. Of 63 subjects, 23 (36.5%) had an "early complete response" profile, which means the achievement of a UAS7 score of "0" within the first 7days of therapy. The most frequent comorbidity was hypertension, which affected 26/63 (41.3%) patients; no adverse events were reported. No significant correlations were found between treatment effectiveness and comorbidities.CONCLUSIONS: omalizumab is a safe and effective therapy also in elderly patients with multiple comorbidities. This article is protected by copyright. All rights reserved.
2021
chronic spontaneous urticaria; drugs aging; elderly; metabolic syndrome; omalizumab
01 Pubblicazione su rivista::01a Articolo in rivista
It's Never Too Late To Treat Chronic Spontaneous Urticaria With Omalizumab: Real-Life Data From A Multicenter Observational Study Focusing on Elderly Patients / Martina, Emanuela; Damiani, Giovanni; Grieco, Teresa; Foti, Caterina; Pigatto, Paolo Daniele Maria; Offidani, Annamaria. - In: DERMATOLOGIC THERAPY. - ISSN 1396-0296. - (2021), p. e14841. [10.1111/dth.14841]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1493887
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 12
social impact